On Nov 06, major Wall Street analysts update their ratings for $Hologic (HOLX.US)$, with price targets ranging from $84 to $95.
Morgan Stanley analyst Tejas Savant maintains with a hold rating, and maintains the target price at $84.
J.P. Morgan analyst Casey Woodring maintains with a buy rating, and adjusts the target price from $92 to $94.
Mizuho Securities analyst Anthony Petrone maintains with a buy rating, and adjusts the target price from $90 to $87.
Raymond James analyst Andrew Cooper maintains with a buy rating, and adjusts the target price from $85 to $95.
Leerink Partners analyst Puneet Souda maintains with a buy rating, and maintains the target price at $90.
Furthermore, according to the comprehensive report, the opinions of $Hologic (HOLX.US)$'s main analysts recently are as follows:
The forecast for Hologic following its Q4 outcomes and initial FY25 guidance is considered to be 'achievable,' and the aim for an operating margin in the low 30% range is seen as 'realistic.' It is also noted that the company's focus on mergers and acquisitions, as well as share buybacks, is still regarded as 'preferable.' Additionally, Hologic's management has emphasized its initiatives to grow into new international markets, despite these often yielding lower margins compared to its U.S. operations.
The company's fiscal Q4 results were a mix, with the stock's valuation currently at a discount, strength in its fundamental operations, and absence of GLP-1 exposure being cited as reasons for maintaining a positive outlook on the shares.
Here are the latest investment ratings and price targets for $Hologic (HOLX.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月6日，多家華爾街大行更新了$豪洛捷 (HOLX.US)$的評級，目標價介於84美元至95美元。
摩根士丹利分析師Tejas Savant維持持有評級，維持目標價84美元。
摩根大通分析師Casey Woodring維持買入評級，並將目標價從92美元上調至94美元。
瑞穗證券分析師Anthony Petrone維持買入評級，並將目標價從90美元下調至87美元。
瑞傑金融分析師Andrew Cooper維持買入評級，並將目標價從85美元上調至95美元。
Leerink Partners分析師Puneet Souda維持買入評級，維持目標價90美元。
此外，綜合報道，$豪洛捷 (HOLX.US)$近期主要分析師觀點如下：
根據豪洛捷第四季的業績和2025財年初期指引，預期該公司的預測爲「可實現的」，並且在低30%的營業利潤率區間內的目標被視爲「現實的」。同時，該公司專注於併購和股票回購的做法仍然被認爲是「可取的」。此外，豪洛捷的管理層強調了其進軍新國際市場的舉措，儘管這些市場往往產生的利潤率較其美國業務低。
該公司財季第四季的業績融合了多種因素，目前股票估值折讓，基本運營強勁，並且不受GLP-1暴露的影響被列爲保持對股票樂觀的理由。
以下爲今日5位分析師對$豪洛捷 (HOLX.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
